Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions: Our data revealbiological and functional interactions between immunotherapy and radiotherapy through the miR-195/-16 family regulatory cascade.Cell Physiol Biochem 2018;48:801 –814
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Publication date: Available online 19 July 2018Source: CellAuthor(s): Ping Gao, Ji-Han Xia, Csilla Sipeky, Xiao-Ming Dong, Qin Zhang, Yuehong Yang, Peng Zhang, Sara Pereira Cruz, Kai Zhang, Jing Zhu, Hang-Mao Lee, Sufyan Suleman, Nikolaos Giannareas, Song Liu, The PRACTICAL Consortium, Teuvo L.J. Tammela, Anssi Auvinen, Xiaoyue Wang, Qilai Huang, Liguo Wang, Aki ManninenSummaryGenome-wide association studies (GWAS) have identified rs11672691 at 19q13 associated with aggressive prostate cancer (PCa). Here, we independently confirmed the finding in a cohort of 2,738 PCa patients and discovered the biological mechanism u...
Source: Cell - Category: Cytology Source Type: research
Publication date: Available online 19 July 2018Source: CellAuthor(s): Junjie Tony Hua, Musaddeque Ahmed, Haiyang Guo, Yuzhe Zhang, Sujun Chen, Fraser Soares, Jennifer Lu, Stanley Zhou, Miranda Wang, Hui Li, Nicholas B. Larson, Shannon K. McDonnell, Parasvi S. Patel, Yi Liang, Cindy Q. Yao, Theodorus van der Kwast, Mathieu Lupien, Felix Y. Feng, Amina Zoubeidi, Ming-Sound TsaoSummaryThe prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a short isoform of long noncoding RNA PCAT19 (PCAT19-short), which is in th...
Source: Cell - Category: Cytology Source Type: research
Publication date: Available online 19 July 2018Source: CellAuthor(s): David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J. Alumkal, Adam Foye, Vishal Kothari, Marc D. Perry, Adina M. Bailey, Denise Playdle, Travis J. Barnard, Li Zhang, Jin Zhang, Jack F. Youngren, Marcin P. Cieslik, Abhijit Parolia, Tomasz M. Beer, George Thomas, Kim N. ChiSummaryWhile mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resista...
Source: Cell - Category: Cytology Source Type: research
Conclusion: The work presented here strongly indicates that temporal order has substantial impact on TeUS performance; thus, it plays a significant role in conveying tissue-specific information. Furthermore, shorter TeUS signals can relay sufficient information to accurately distinguish between tissue types. Significance: Understanding the impact of TeUS properties facilitates the process of its a- opting in diagnostic procedures and provides insights on improving its acquisition.
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Conclusion18F-PSMA-1007 PET/CT can detect recurrent PCa in a high percentage of patients with biochemical relapse. The probability of a pathological18F-PSMA-1007 PET/CT scan seems to be high even in patients with a low PSA level ≤0.5 ng/ml, and this may have a significant impact on the management of this relevant group of patients.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Publication date: Available online 19 July 2018Source: European UrologyAuthor(s): Parth K. Modi, Todd M. Morgan
Source: European Urology - Category: Urology & Nephrology Source Type: research
CONCLUSION: Neither elevated NLR nor PLR predicted an increased risk of BCR. PMID: 30019909 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Authors: Ploussard G, de la Taille A Abstract INTRODUCTION: The prostate cancer antigen 3 (PCA3) score has been the first urine assay to obtain the Food and Drug Administration approval for guiding decisions regarding additional biopsies. Different aspects of this urinary assay (diagnostic performance, prognostic value, cost/benefit balance, integration with other molecular and imaging modalities) have now been well evaluated. Areas covered: This expert review will summarize current achievements and future perspectives provided by this urine biomarker. Expert commentary: The clinical benefit of the PCA3 score, in a...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Conditions:   Solid Tumor;   Hepatocellular Carcinomas (HCC);   Castrate-resistant Prostate Cancer (CRPC) Intervention:   Drug: OBI-3424 Sponsor:   OBI Pharma, Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Pharmaceuticals | Prostate Cancer